FDA Approves Sanofi's Tzield for Children With Stage 3 Diabetes

The FDA has approved Sanofi's teplizumab, sold as Tzield, for children with stage 3 type 1 diabetes, broadening access to a drug previously cleared for delaying disease onset in higher-risk patients, according to STAT News.

The decision is notable as much for the process as the product. STAT reports the approval came after a dispute inside the agency, pitting career staff against the political appointee who leads the Center for Drug Evaluation and Research (CDER). That tension highlights how regulatory calls that were once routine science questions are increasingly entangled with leadership and political dynamics at the FDA.

For Sanofi, the expanded label opens a larger pediatric market for a therapy aimed at modifying the course of type 1 diabetes rather than just managing blood sugar. For the broader industry, the episode is a signal that sponsors and investors should watch internal FDA governance closely, since the path from data to approval now runs through contested leadership decisions, not just clinical review.